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Background
The ryanodine receptor type 1 (RyR1) is one of the biggest
known muscle proteins (4 x 565 kDa) acting as the major
calcium release channel of skeletal muscle. A large num-
ber of mutations have been identified in the corresponding
gene (RYR1) giving rise to a variety of clinical phenotypes:
Malignant Hyperthermia susceptibility (MHS) and the
group of congenital (core) myopathies.
Materials and methods
In 1992, we began to screen MHS individual by PCR and
restriction enzyme digestion for the few then known
RYR1 mutations. At around 1995, we switched to Sanger
sequencing of selected exons (mutation hot-spots) and
for a number of years, we analysed five exons in MHS
(exons 17, 39, 40, 45, 46) and four in myopathic subjects
(exons 95, 100, 101, 102). From 2002 on, we also
included whole-gene sequencing of all 106 exons by San-
ger or NGS technologies (starting from 2011). In total,
we have screened 1.029 unrelated index cases. The great
majority of malignant hyperthermia (MH) individuals
had a positive in vitro contracture test (IVCT) result
(MHS or MH equivocal (MHE)) or a likely clinical MH
episode. Patients with congenital myopathies were
referred on the basis of their clinical presentation.
Results
Among the 305 individuals screened for the MHS hot-
spot, we identified 16 different sequence variants in 46
individuals (15,8 %). In 41 patients, the mutation met the
criteria for causality of the European MH group (EMHG)
leaving only 5 individuals with unclassified variants.
In the myopathy group of 474 index cases, 37 variants
were identified in 72 individuals by screening the “CCD-
hot-spot” (15,2 %). In this group, only three mutations
in 16 patients fulfilled the causality criteria of EMHG.
Thus, for 56 individuals, the screening gave no clear-cut
results.
Of note, all variants in the first two groups were single
and of heterozygous genotype.
After switching to whole-gene analysis, 250 individuals
of either clinical phenotype were analysed. At total of
101 variants were found in 90 patients (36 %). Of those,
54 variants in 71 subjects were single and heterozygous,
while ten patients had two, five had three and three
patients four variants each. Only 18 patients carried ten
bona fide (EMHG) mutations.
The recurrency rates of mutations were low: of the
140 different variants observed, only 17 occurred more
than once and only seven more than twice covering just
59 patients.
Conclusions
Our longitudinal study reflects the known allelic heteroge-
neity of RYR1 mutations which poses a challenge for effec-
tive variant identification strategies to the present day.
Although labor and cost have decreased with the advent
of novel technologies, the problem of variant interpreta-
tion has increased proportional to the range and sensitivity
of the screening methods. Since the vast majority of RYR1
variants result in amino acid substitutions their functional
impact is not immediately evident. The causality criteria
set by the EMHG are very strict in order to maximize clin-
ical safety but this is in contrast to current practice in
most other genetically heterogeneous disorders. In fact,
the majority of “unclassified” variants identified in this
study have been published in association with MHS and/
or congenital myopathies and many of them meet all but
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one of the EMHG criteria. The reliability of computer
algorithms for predicting the impact of amino acid substi-
tutions on protein function has greatly improved but is
still limited for large proteins like RyR1.
It is fair to say that the initial hope of genetic analysis
eventually replacing the invasive IVCT has proven vain for
the majority of cases. Similarly, a quick & cheap MH test
which could be used the night before anesthesia will – if it
ever comes true – most likely not be based on genetic
analysis.
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